We showed that the administration of the same Bifidobacterium cocktail previously used by Sivan et al. to potentiate PD-L1 therapy [5] was sufficient to enhance the antitumor activity of a cancer vaccine comprising OMVs formulated with five mutation-derived neo-epitopes. This evidence concerns the gene CD274 and cancer.